Search research articles
Contact Us
Filters
Showing results (111-120 of 140) with videos related to
Page
of 14
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 2022
Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial
Olive S Eckstein, Carl E Allen, P Mickey Williams, et al.
JCO Precision Oncology
|
June 27, 2024
Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial
Kieuhoa T Vo, Amit J Sabnis, P Mickey Williams, et al.
JCO Precision Oncology
|
February 8, 2024
Influence of <i>TP53</i> Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in <i>STK11</i>-Mutant Non-Small-Cell Lung Cancer
Abdul Rafeh Naqash, Charalampos S Floudas, Etan Aber, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 17, 2021
Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors
Naoko Takebe, Abdul Rafeh Naqash, Geraldine O'Sullivan Coyne, et al.
Cancer Research
|
April 29, 2026
KRAS Signaling Inhibition Induces a Targetable Metabolic Dependency on Lipophagy-Dependent Fatty Acid Oxidation in Pancreatic Cancer
Ravi Thakur, Dezhen Wang, Tuo Hu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 30, 2022
Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial
D Williams Parsons, Katherine A Janeway, David R Patton, et al.
Cancer Chemotherapy and Pharmacology
|
March 14, 2026
Phase I trial of the combination of bortezomib and clofarabine in adults with refractory tumors
Jibran Ahmed, Andre DeSouza, Shivaani Kummar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 4, 2015
Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer
Daniel V T Catenacci, Melissa R Junttila, Theodore Karrison, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 15, 2015
Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032
Giles W Robinson, Brent A Orr, Gang Wu, et al.
JCO Precision Oncology
|
September 19, 2024
Phase II Study of Samotolisib in Children and Young Adults With Tumors Harboring Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Pathway Alterations: Pediatric MATCH APEC1621D
Theodore W Laetsch, Kathleen Ludwig, P Mickey Williams, et al.
Page
of 14
Search research articles
Search
Showing results (111-120 of 140) with videos related to
Sort By:
Page
of 14
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 2022
Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial
Olive S Eckstein, Carl E Allen, P Mickey Williams, et al.
JCO Precision Oncology
|
June 27, 2024
Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial
Kieuhoa T Vo, Amit J Sabnis, P Mickey Williams, et al.
JCO Precision Oncology
|
February 8, 2024
Influence of <i>TP53</i> Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in <i>STK11</i>-Mutant Non-Small-Cell Lung Cancer
Abdul Rafeh Naqash, Charalampos S Floudas, Etan Aber, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 17, 2021
Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors
Naoko Takebe, Abdul Rafeh Naqash, Geraldine O'Sullivan Coyne, et al.
Cancer Research
|
April 29, 2026
KRAS Signaling Inhibition Induces a Targetable Metabolic Dependency on Lipophagy-Dependent Fatty Acid Oxidation in Pancreatic Cancer
Ravi Thakur, Dezhen Wang, Tuo Hu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 30, 2022
Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial
D Williams Parsons, Katherine A Janeway, David R Patton, et al.
Cancer Chemotherapy and Pharmacology
|
March 14, 2026
Phase I trial of the combination of bortezomib and clofarabine in adults with refractory tumors
Jibran Ahmed, Andre DeSouza, Shivaani Kummar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 4, 2015
Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer
Daniel V T Catenacci, Melissa R Junttila, Theodore Karrison, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 15, 2015
Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032
Giles W Robinson, Brent A Orr, Gang Wu, et al.
JCO Precision Oncology
|
September 19, 2024
Phase II Study of Samotolisib in Children and Young Adults With Tumors Harboring Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Pathway Alterations: Pediatric MATCH APEC1621D
Theodore W Laetsch, Kathleen Ludwig, P Mickey Williams, et al.
Page
of 14